Peter Kaspar
Directeur/Membre du Conseil chez First Light Diagnostics, Inc.
Profil
Peter Kaspar is currently a Director at First Light Diagnostics, Inc. He previously held Director positions at Biotheranostics, Inc., Daktari Diagnostics, Inc., and Sloning Bio Technology GmbH.
He was also a Non-Executive Director at Immunodiagnostic Systems Holdings Ltd.
and a Corporate Vice President-Microbiology at bioMérieux SA. Dr. Kaspar earned a doctorate degree from the University of Münster.
Postes actifs de Peter Kaspar
| Sociétés | Poste | Début |
|---|---|---|
First Light Diagnostics, Inc.
 First Light Diagnostics, Inc. Information Technology ServicesTechnology Services First Light Diagnostics, Inc. develops automated medical diagnostic products for the detection of microbes that cause healthcare and hospital infections. The firm offers MultiPath technology detects and counts fluorescent targets without using magnification. Its MultiPath technology is used for screening, blood infections, surgical infections, skin infections and GI infections. The company was founded by Donald Straus and is headquartered in Bedford, MA. | Directeur/Membre du Conseil | 01/01/2019 |
Anciens postes connus de Peter Kaspar
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNODIAGNOSTIC SYSTEMS HOLDINGS PLC | Directeur/Membre du Conseil | - |
Daktari Diagnostics, Inc.
 Daktari Diagnostics, Inc. Medical SpecialtiesHealth Technology Daktari Diagnostics, Inc. operates as a holding company that provides healthcare solutions. The firm engages in the development of point-of-care diagnostic systems for global health applications. Its product includes Daktari Virology which detects HIV and HCV, Daktari InSight which provides data management services, and Daktari Sickle Cell which detects sickle cell disease on infants. The company was founded by William Rodriguez in 2008 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | - |
Biotheranostics, Inc.
 Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | - |
| BIOMÉRIEUX | Corporate Officer/Principal | - |
Sloning Bio Technology GmbH
 Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | Corporate Officer/Principal | - |
Formation de Peter Kaspar
| University of Münster | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOMÉRIEUX | Health Technology |
| Entreprise privées | 5 |
|---|---|
Sloning Bio Technology GmbH
Sloning Bio Technology GmbH Miscellaneous Commercial ServicesCommercial Services Sloning BioTechnology specializes in the production of highly genetically diverse and precise customized libraries. The company offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. As a business specializing in the development and production of genetically diverse libraries, Sloning BioTechnology GmbH offers high quality, innovative, tailored protein engineering solutions to its industrial and biopharmaceutical customers worldwide. The firm's Slonomics core technology is a unique DNA engineering platform that uses defined sets of double stranded DNA triplets to precisely introduce the required mutations into any DNA sequence. This multiply validated technology takes a novel approach to enable the realization of highly complex design concepts while at the same time ensuring that libraries generated by Sloning have the very highest standards of reliability. It harnesses the capabilities of Slonomics to synthesize SlonoMax and SlonoMax libraries are customized mutant libraries that significantly improve the efficiency of screening for new and improved proteins for therapeutic, enzymatic or technical applications. In addition, it offers a premium gene synthesis service using Slonomics for its industrial clients. SlonoGene is a tailored service offering gene customization and optimization suited perfectly to the needs of its customers. | Commercial Services |
Biotheranostics, Inc.
Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | Health Services |
Daktari Diagnostics, Inc.
Daktari Diagnostics, Inc. Medical SpecialtiesHealth Technology Daktari Diagnostics, Inc. operates as a holding company that provides healthcare solutions. The firm engages in the development of point-of-care diagnostic systems for global health applications. Its product includes Daktari Virology which detects HIV and HCV, Daktari InSight which provides data management services, and Daktari Sickle Cell which detects sickle cell disease on infants. The company was founded by William Rodriguez in 2008 and is headquartered in Cambridge, MA. | Health Technology |
Immunodiagnostic Systems Holdings Ltd.
 Immunodiagnostic Systems Holdings Ltd. Medical SpecialtiesHealth Technology Immunodiagnostic Systems Holdings Plc engages in the development, manufacture, and marketing of in-vitro diagnostic tests (IVD) to the clinical laboratory market. The company was founded in 1977 and is headquartered in Boldon, the United Kingdom. | Health Technology |
First Light Diagnostics, Inc.
First Light Diagnostics, Inc. Information Technology ServicesTechnology Services First Light Diagnostics, Inc. develops automated medical diagnostic products for the detection of microbes that cause healthcare and hospital infections. The firm offers MultiPath technology detects and counts fluorescent targets without using magnification. Its MultiPath technology is used for screening, blood infections, surgical infections, skin infections and GI infections. The company was founded by Donald Straus and is headquartered in Bedford, MA. | Technology Services |
